polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride
NULYTELY (polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride) by R-Pharm US is osmotic activity [moa]. First approved in 1991.
Drug data last refreshed 2m ago · AI intelligence enriched 1h ago
NULYTELY is an oral polyethylene glycol (PEG) 3350-based bowel preparation solution indicated for colonoscopy preparation. It works through osmotic activity to cleanse the colon by drawing water into the intestinal lumen, producing a laxative effect without systemic absorption.
Mature, commoditized market with minimal growth; teams focused on cost-efficiency and market defense rather than expansion.
Osmotic Activity
Osmotic Laxative
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on NULYTELY offers limited career growth within pharma; roles are transactional and focused on defending market share in a commoditized category. This is typically a defensive/maintenance assignment rather than a platform for advancement into innovation-focused positions.
Worked on NULYTELY at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo